{
    "hands_on_practices": [
        {
            "introduction": "Accurate diagnosis is the cornerstone of effective management for anogenital lesions. This exercise simulates a real-world clinical challenge, requiring you to synthesize patient history, physical examination findings, and definitive histopathology results. By correctly identifying the condition and distinguishing it from its more sinister mimics like high-grade intraepithelial lesions or invasive carcinoma, you will practice the critical reasoning needed for developing a comprehensive and appropriate management plan .",
            "id": "4412569",
            "problem": "A patient aged $29$ years, who is immunocompetent and not pregnant, presents with multiple, exophytic, skin-colored papules clustered on the vulvar vestibule and perineum. The lesions have a verrucous, cauliflower-like surface and have slowly enlarged over $4$ months. She uses condoms inconsistently and has no systemic symptoms. Baseline laboratory testing is negative for Human Immunodeficiency Virus (HIV) and syphilis. Cervical cancer screening $1$ year ago was normal. Because the lesions were atypically confluent and to establish a definitive diagnosis, a shave biopsy of one representative papule was performed.\n\nHistopathologic report:\n- Marked acanthosis with elongation of rete ridges.\n- Papillomatosis and parakeratosis.\n- Numerous koilocytes in the upper spinous and superficial layers, with perinuclear halos and nuclear irregularity.\n- No stromal invasion; basement membrane remains intact.\n- Mitoses confined to the basal and parabasal layers without atypical forms.\n\nBased solely on the above histopathologic features integrated with the epidemiology and pathobiology of Human Papillomavirus (HPV) infection, identify the most accurate diagnosis and the most appropriate next management step for this patient.\n\nA. Condyloma acuminatum (anogenital warts) due to low-risk HPV types $6/11$; offer either patient-applied imiquimod $5\\%$ cream $3$ times per week for up to $16$ weeks or provider-administered destructive therapy such as cryotherapy or trichloroacetic acid, with counseling on transmission, recurrence, screening for other Sexually Transmitted Infections (STIs), and consideration of HPV vaccination if not previously immunized.\n\nB. Vulvar high-grade squamous intraepithelial lesion (HSIL; bowenoid papulosis) associated with HPV types $16/18$; proceed to wide local excision with oncologic margins and referral to gynecologic oncology.\n\nC. Invasive squamous cell carcinoma of the vulva; perform radical excision with sentinel lymph node mapping and cross-sectional imaging for staging.\n\nD. Molluscum contagiosum; perform curettage of all lesions and reassure that no further evaluation is necessary beyond routine care.\n\nE. Condyloma acuminatum; initiate podofilox (podophyllotoxin) in pregnancy as first-line therapy and defer STI counseling because partner treatment is mandatory for cure.",
            "solution": "The problem statement will first be validated for scientific soundness, completeness, and objectivity before a solution is attempted.\n\n### Step 1: Extract Givens\n\n-   **Patient Profile**: Age $29$ years, immunocompetent, not pregnant.\n-   **Clinical Presentation**: Multiple, exophytic, skin-colored papules clustered on the vulvar vestibule and perineum. The surface is described as verrucous and cauliflower-like. The lesions have shown slow enlargement over a period of $4$ months.\n-   **Risk Factors**: Inconsistent condom use.\n-   **Symptoms**: No systemic symptoms.\n-   **Laboratory/Screening Data**: Human Immunodeficiency Virus (HIV) negative, syphilis negative. Cervical cancer screening $1$ year ago was normal.\n-   **Procedure**: A shave biopsy of a representative papule was performed.\n-   **Histopathologic Findings**:\n    1.  Marked acanthosis with elongation of rete ridges.\n    2.  Papillomatosis and parakeratosis.\n    3.  Numerous koilocytes in the upper spinous and superficial layers, characterized by perinuclear halos and nuclear irregularity.\n    4.  No stromal invasion; the basement membrane is intact.\n    5.  Mitoses are confined to the basal and parabasal layers, and no atypical forms are present.\n-   **Question**: Identify the most accurate diagnosis and the most appropriate next management step based on the integration of histopathology, epidemiology, and pathobiology.\n\n### Step 2: Validate Using Extracted Givens\n\n-   **Scientific Grounding**: The problem describes a classic case of anogenital warts. The clinical description (exophytic, verrucous, cauliflower-like papules in the anogenital area) and the patient's risk factor (inconsistent condom use) are typical for condyloma acuminatum. The histopathologic findings are pathognomonic for Human Papillomavirus (HPV) infection: acanthosis (thickening of the epidermis), papillomatosis (undulation of the epidermis), and koilocytosis (vacuolated keratinocytes with irregular nuclei) are the hallmark features. The mention of an intact basement membrane and mitoses confined to the basal layer correctly points towards a benign process, distinguishing it from invasive carcinoma or high-grade dysplasia. The entire scenario is scientifically and medically accurate.\n-   **Well-Posedness**: The problem provides a complete set of data—patient demographics, clinical findings, and definitive histopathology—sufficient to establish a diagnosis and formulate a management plan. A unique, standard-of-care-based answer is determinable.\n-   **Objectivity**: The problem uses precise, standard medical terminology (e.g., \"acanthosis,\" \"koilocytes,\" \"papillomatosis\") and is free from subjective or ambiguous language.\n\n### Step 3: Verdict and Action\n\nThe problem statement is valid. It is scientifically sound, well-posed, and objective, presenting a realistic clinical scenario in dermatology and venereology. I will now proceed with the derivation of the solution and evaluation of the options.\n\n### Derivation of Diagnosis and Management Plan\n\n1.  **Diagnosis**: The combination of clinical and histopathological findings leads to a definitive diagnosis.\n    -   The clinical appearance of \"exophytic, verrucous, cauliflower-like\" papules in the anogenital region is quintessential for **Condyloma Acuminatum** (anogenital warts).\n    -   The histology confirms this diagnosis. Koilocytes are cells that have undergone cytopathic changes due to HPV infection and are the histologic sine qua non of this condition. The other features—acanthosis, papillomatosis, and parakeratosis—are supportive findings for a verrucous lesion caused by HPV.\n    -   The absence of stromal invasion and the confinement of non-atypical mitoses to the basal layer rule out invasive squamous cell carcinoma and high-grade squamous intraepithelial lesion (HSIL), respectively.\n    -   Epidemiologically, over $90\\%$ of anogenital warts are caused by **low-risk HPV types $6$ and $11$**. High-risk types (e.g., $16, 18$) are the primary cause of cervical cancer and other anogenital malignancies but are less commonly associated with classic exophytic condylomata.\n\n2.  **Management**: The management strategy must be based on standard evidence-based guidelines (e.g., from the CDC) for a non-pregnant, immunocompetent patient.\n    -   **Treatment of Lesions**: The goal is the removal of symptomatic warts. There is no single superior treatment. Options are categorized as patient-applied or provider-administered.\n        -   **Patient-applied**: Imiquimod $5\\%$ cream, podofilox $0.5\\%$ solution/gel, or sinecatechins $15\\%$ ointment.\n        -   **Provider-administered**: Cryotherapy with liquid nitrogen, trichloroacetic acid (TCA) or bichloroacetic acid (BCA) application, or surgical removal (e.g., shave excision, curettage, electrosurgery).\n        -   Offering the patient a choice between these categories is considered best practice.\n    -   **Comprehensive Care**: Management extends beyond lesion removal.\n        -   **Counseling**: The patient must be counseled that treatments address the visible warts but may not eradicate the underlying HPV infection, so recurrences are common. Transmission (primarily sexual) and prevention (condoms reduce but do not eliminate risk) must be discussed.\n        -   **STI Screening**: Diagnosis of any STI warrants screening for others. While HIV and syphilis are negative, screening for chlamydia and gonorrhea is indicated.\n        -   **HPV Vaccination**: The patient is $29$ years old. The 9-valent HPV vaccine is approved for individuals up to age $45$, with shared clinical decision-making recommended for those aged $27-45$. Vaccination would be beneficial as it protects against other HPV types in the vaccine (including high-risk types $16, 18$) she may not have been exposed to.\n\n### Evaluation of Options\n\n-   **A. Condyloma acuminatum (anogenital warts) due to low-risk HPV types $6/11$; offer either patient-applied imiquimod $5\\%$ cream $3$ times per week for up to $16$ weeks or provider-administered destructive therapy such as cryotherapy or trichloroacetic acid, with counseling on transmission, recurrence, screening for other Sexually Transmitted Infections (STIs), and consideration of HPV vaccination if not previously immunized.**\n    -   **Diagnosis**: Correct. The diagnosis and likely etiology are accurately stated.\n    -   **Management**: Correct. Presents a standard choice between a valid patient-applied therapy (imiquimod) and valid provider-administered therapies (cryotherapy, TCA). The specific regimen for imiquimod is also correct.\n    -   **Counseling/Ancillary Care**: Correct. It includes all essential components of comprehensive care.\n    -   **Verdict**: **Correct**.\n\n-   **B. Vulvar high-grade squamous intraepithelial lesion (HSIL; bowenoid papulosis) associated with HPV types $16/18$; proceed to wide local excision with oncologic margins and referral to gynecologic oncology.**\n    -   **Diagnosis**: Incorrect. The histopathology, specifically the confinement of normal mitoses to the basal layer and the absence of significant nuclear atypia throughout the epithelium, is inconsistent with HSIL.\n    -   **Management**: Incorrect. This is overly aggressive treatment for the diagnosed condition.\n    -   **Verdict**: **Incorrect**.\n\n-   **C. Invasive squamous cell carcinoma of the vulva; perform radical excision with sentinel lymph node mapping and cross-sectional imaging for staging.**\n    -   **Diagnosis**: Incorrect. The histopathology report explicitly states \"No stromal invasion; basement membrane remains intact,\" which by definition rules out invasive carcinoma.\n    -   **Management**: Incorrect. This is the treatment for invasive cancer and is entirely inappropriate.\n    -   **Verdict**: **Incorrect**.\n\n-   **D. Molluscum contagiosum; perform curettage of all lesions and reassure that no further evaluation is necessary beyond routine care.**\n    -   **Diagnosis**: Incorrect. The clinical description (cauliflower-like) and histopathology (koilocytes) do not match molluscum contagiosum, which presents as umbilicated papules and shows Henderson-Patterson bodies on histology.\n    -   **Management**: Incorrect. The diagnosis is wrong, and dismissing the need for STI counseling for a newly diagnosed sexually transmitted infection is substandard care.\n    -   **Verdict**: **Incorrect**.\n\n-   **E. Condyloma acuminatum; initiate podofilox (podophyllotoxin) in pregnancy as first-line therapy and defer STI counseling because partner treatment is mandatory for cure.**\n    -   **Diagnosis**: The diagnosis of \"Condyloma acuminatum\" is correct.\n    -   **Management & Counseling**: This section contains multiple critical errors. The patient is stated to be **not pregnant**. Furthermore, podofilox is **contraindicated** in pregnancy. STI counseling should never be deferred. Finally, partner treatment is not considered mandatory for cure of the patient's lesions, and this statement is misleading.\n    -   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Beyond diagnosis, a sophisticated understanding of pathogenesis is essential, especially with the widespread use of molecular testing. This problem presents a common clinical scenario: a co-infection with both a low-risk and a high-risk Human Papillomavirus (HPV) genotype, both detected by Polymerase Chain Reaction (PCR). Your task is to apply your knowledge of genotype-phenotype correlations and viral life cycles to determine which virus is the principal architect of the observed benign wart, thereby deepening your grasp of HPV's distinct biological pathways .",
            "id": "4412493",
            "problem": "A patient presents with multiple exophytic, papillomatous anogenital lesions clinically consistent with condyloma acuminata. Histopathology shows acanthosis, papillomatosis, parakeratosis, and prominent koilocytosis without features of high-grade dysplasia. Tissue Polymerase Chain Reaction (PCR) is positive for Human Papillomavirus (HPV) genotype $6$ (HPV$6$) and genotype $16$ (HPV$16$). Based on established genotype–phenotype correlations and the biology of HPV infection in stratified squamous epithelium, which viral genotype is most likely the principal driver of the exophytic lesion phenotype, and why?\n\nChoose the single best answer.\n\nA. HPV$6$ is the primary driver because low-risk genotypes typically maintain episomal genomes with productive replication and high late capsid protein ($L1$/$L2$) expression in differentiated keratinocytes, yielding papillomatous growth, whereas HPV$16$ is more often linked to transforming infections that present as flat or dysplastic lesions.\n\nB. HPV$16$ is the primary driver because its $E6$/$E7$ oncoproteins more potently deregulate the cell cycle, producing greater hyperproliferation and exophytic verrucous growth than HPV$6$.\n\nC. Both HPV$6$ and HPV$16$ are equally likely drivers because PCR positivity indicates co-dominant replication in the wart tissue regardless of genotype.\n\nD. No inference is possible solely from genotype detection; the driver cannot be determined without quantitative viral load or integration status data.\n\nE. Neither HPV$6$ nor HPV$16$ drives the phenotype; the exophytic morphology is primarily due to host inflammation and is independent of HPV genotype.",
            "solution": "The problem statement will first be validated for scientific soundness, consistency, and clarity.\n\n**Step 1: Extract Givens**\n*   **Clinical Presentation**: Multiple exophytic, papillomatous anogenital lesions.\n*   **Clinical Impression**: Condyloma acuminata.\n*   **Histopathology**: Acanthosis, papillomatosis, parakeratosis, and prominent koilocytosis. Explicitly states \"without features of high-grade dysplasia\".\n*   **Molecular Data**: Tissue Polymerase Chain Reaction (PCR) is positive for Human Papillomavirus (HPV) genotype $6$ (HPV$6$) and genotype $16$ (HPV$16$).\n*   **Question**: Identify the most likely principal driver of the exophytic lesion phenotype based on established genotype-phenotype correlations and HPV biology.\n\n**Step 2: Validate Using Extracted Givens**\n*   **Scientific Grounding**: The problem is scientifically grounded. It describes a common clinical scenario involving a co-infection with low-risk and high-risk HPV types. The terminology (condyloma acuminata, acanthosis, papillomatosis, koilocytosis, dysplasia, HPV genotypes) is standard in pathology, dermatology, and virology. The distinction between the pathogenic pathways of low-risk HPV (LR-HPV) and high-risk HPV (HR-HPV) is a fundamental concept in the field.\n*   **Well-Posedness**: The problem is well-posed. It presents a specific set of clinical and laboratory findings and asks for the most probable causal explanation based on established scientific principles. The question seeks an inference about the \"principal driver,\" which is a legitimate and answerable question in biology, where multiple factors can be present but one is dominant in creating a specific phenotype.\n*   **Objectivity**: The problem is stated in objective, scientific language. It is free from ambiguity, subjectivity, or non-scientific claims.\n\n**Step 3: Verdict and Action**\n*   **Verdict**: The problem is valid. It is a well-formed question that tests the understanding of HPV pathogenesis and its clinical-pathological correlation.\n*   **Action**: Proceed to a full solution and analysis of options.\n\n**Derivation of the Solution**\n\nThe solution requires correlating the observed phenotype (clinical and histological) with the known biological activities of the detected viral genotypes, HPV$6$ and HPV$16$.\n\n$1$. **Phenotype Analysis**: The patient presents with \"exophytic, papillomatous\" lesions. Histopathology confirms this with \"acanthosis\" (thickening of the spinous layer), \"papillomatosis\" (undulating, finger-like projections of the epidermis), and \"prominent koilocytosis\". Koilocytes are keratinocytes that show characteristic cytopathic effects of a productive HPV infection, including a perinuclear halo and a wrinkled, hyperchromatic nucleus. Crucially, the biopsy shows \"without features of high-grade dysplasia\". This entire constellation of findings is the classic definition of condyloma acuminatum, a benign papilloma.\n\n$2$. **Genotype Biology and Correlation**:\n    *   **HPV$6$**: This is a canonical low-risk HPV (LR-HPV) genotype. LR-HPVs are the primary cause of anogenital warts (condyloma acuminata). Their life cycle is typically \"productive\". The viral genome is maintained as an extrachromosomal element, or episome, in the basal keratinocytes. As these cells differentiate and migrate to the epithelial surface, the viral life cycle progresses, leading to expression of early (E) proteins that stimulate benign cell proliferation, and late (L) proteins (`$L1$` and `$L2$`) that form new virions in the uppermost layers. This ordered, productive process directly results in the papillomatous architecture and prominent koilocytosis seen in the patient's biopsy.\n    *   **HPV$16$**: This is the most oncogenic high-risk HPV (HR-HPV) genotype. While HR-HPVs can cause productive infections, their notoriety stems from their ability to cause \"transforming\" infections that can lead to cancer. This process is driven by the potent oncoproteins E$6$ and E$7$. HPV$16$ E$6$ targets tumor suppressor p$53$ for degradation, and E$7$ targets retinoblastoma protein (pRb). The dysregulation of these key cell cycle checkpoints leads to uncontrolled proliferation, genomic instability, and cellular atypia, which manifests histologically as dysplasia (e.g., squamous intraepithelial lesion, SIL). Clinically, HR-HPV-driven dysplastic lesions are often flat or only slightly raised, not prominently exophytic and papillomatous like classic warts.\n\n$3$. **Synthesis**: The observed phenotype is a benign, productive lesion (classic condyloma acuminatum). This phenotype is the archetypal manifestation of an LR-HPV infection, such as by HPV$6$. The phenotype is inconsistent with a process primarily driven by the oncogenic proteins of HPV$16$, which would be expected to produce dysplasia rather than ordered papillomatosis and koilocytosis. Therefore, even though HPV$16$ DNA is present (indicating co-infection), the principal architect of the lesion's morphology is HPV$6$. The HPV$16$ infection may be latent, transient, or represent a minor, non-transforming component within the larger HPV$6$-driven lesion.\n\n**Evaluation of Options**\n\n*   **A. HPV$6$ is the primary driver because low-risk genotypes typically maintain episomal genomes with productive replication and high late capsid protein ($L1$/$L2$) expression in differentiated keratinocytes, yielding papillomatous growth, whereas HPV$16$ is more often linked to transforming infections that present as flat or dysplastic lesions.**\n    This option accurately describes the fundamental dichotomy in HPV pathogenesis. It correctly associates the LR-HPV type (HPV$6$) with the productive life cycle that generates the observed papillomatous phenotype. It also correctly contrasts this with the typical association of HR-HPV type (HPV$16$) with transforming infections and dysplastic, flatter lesions. This reasoning aligns perfectly with the derivation above.\n    **Verdict: Correct**\n\n*   **B. HPV$16$ is the primary driver because its $E6$/$E7$ oncoproteins more potently deregulate the cell cycle, producing greater hyperproliferation and exophytic verrucous growth than HPV$6$.**\n    This statement makes an incorrect causal link. While HPV$16$ E$6$/E$7$ are indeed more potent, their effect is dysregulated proliferation leading to atypia and dysplasia, not the organized, benign papillomatous growth of a condyloma. The premise that greater oncogenic potency yields larger benign warts is biologically false.\n    **Verdict: Incorrect**\n\n*   **C. Both HPV$6$ and HPV$16$ are equally likely drivers because PCR positivity indicates co-dominant replication in the wart tissue regardless of genotype.**\n    This is incorrect. A simple positive PCR result for DNA does not provide information on viral gene expression, replication level, or biological activity. It merely confirms the presence of the viral genome. The assumption of \"co-dominant replication\" is not supported by the data. The phenotype of the lesion provides strong evidence that one genotype's biological program is dominant.\n    **Verdict: Incorrect**\n\n*   **D. No inference is possible solely from genotype detection; the driver cannot be determined without quantitative viral load or integration status data.**\n    This is an overly conservative and clinically impractical stance. While more advanced molecular tests would provide further confirmation, a strong and reliable inference is a cornerstone of clinical-pathological correlation. The combination of a classic condyloma phenotype with the detection of the classic condyloma-causing virus (HPV$6$) allows for a high-confidence conclusion about the principal driver, even in the presence of a co-infecting virus. The question asks for the \"most likely\" driver, which is answerable with the given information.\n    **Verdict: Incorrect**\n\n*   **E. Neither HPV$6$ nor HPV$16$ drives the phenotype; the exophytic morphology is primarily due to host inflammation and is independent of HPV genotype.**\n    This is fundamentally incorrect. The proliferative and morphological changes that define a wart are directly caused by the actions of HPV viral proteins on the host keratinocytes. While the host immune and inflammatory response modulates the infection, it is not the primary driver of the exophytic phenotype. The phenotype is highly genotype-dependent.\n    **Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "In contemporary medicine, treatment decisions are guided not only by clinical efficacy but also by economic considerations. This exercise provides a practical application of health economics to the management of anogenital warts. You will calculate and interpret the incremental cost-effectiveness ratio ($ICER$) for two standard therapies, a crucial skill for evidence-based resource allocation and for justifying treatment choices within a healthcare system .",
            "id": "4412626",
            "problem": "A sexual health clinic is conducting a short-horizon economic evaluation of two first-line treatments for external anogenital warts (condyloma acuminata) over a time horizon of $12$ weeks, using the healthcare provider perspective and direct medical costs only, with no discounting over this time frame. The two strategies are topical imiquimod cream versus clinic-based cryotherapy. The clinic assumes the following resource utilization and unit costs per patient over $12$ weeks:\n\n- Imiquimod strategy:\n  - Medication (imiquimod $5\\%$ cream): total course cost $=\\$170$.\n  - Clinic visits: $2$ visits at $\\$70$ each.\n  - Symptomatic management for local irritation (emollient and counseling time): $\\$10$ per patient.\n  - Probability of complete wart clearance by week $12$: $0.42$.\n\n- Cryotherapy strategy:\n  - Treatment sessions: $5$ sessions at $\\$90$ each.\n  - Post-procedure dressings and supplies: $5$ packs at $\\$10$ each.\n  - Probability of complete wart clearance by week $12$: $0.58$.\n\nAssume that all patients follow the specified resource use schedule for their assigned strategy, and that the probability of complete clearance represents the effectiveness measure per patient over the $12$-week horizon. Under a standard cost-effectiveness framework, define the incremental cost per additional clearance of cryotherapy relative to imiquimod as the ratio of the difference in mean per-patient costs to the difference in mean per-patient probabilities of complete clearance over $12$ weeks.\n\nCompute this incremental cost per additional clearance for cryotherapy relative to imiquimod. Round your answer to four significant figures. Express the final value in United States dollars (USD) per additional clearance. Do not include the unit in your final numeric answer.",
            "solution": "The problem requires the calculation of the incremental cost per additional clearance for cryotherapy relative to imiquimod. This is a standard calculation in health economics, formally known as the Incremental Cost-Effectiveness Ratio ($ICER$). The analysis is set over a time horizon of $12$ weeks, using only direct medical costs from the healthcare provider's perspective, without discounting.\n\nFirst, we must calculate the total mean cost per patient for each treatment strategy. Let $C_{IMI}$ and $C_{CRYO}$ represent the mean costs for the imiquimod and cryotherapy strategies, respectively.\n\nFor the imiquimod strategy, the total cost $C_{IMI}$ is the sum of the medication cost, the cost of clinic visits, and the cost for symptomatic management. The given values are:\n- Medication cost: $\\$170$.\n- Clinic visits: $2$ visits at a cost of $\\$70$ per visit.\n- Symptomatic management: $\\$10$.\n\nThe total mean cost for the imiquimod strategy is:\n$$C_{IMI} = 170 + (2 \\times 70) + 10$$\n$$C_{IMI} = 170 + 140 + 10 = 320$$\nThus, the mean cost per patient for the imiquimod strategy is $\\$320$.\n\nFor the cryotherapy strategy, the total cost $C_{CRYO}$ is the sum of the cost for treatment sessions and the cost of post-procedure supplies. The given values are:\n- Treatment sessions: $5$ sessions at a cost of $\\$90$ per session.\n- Post-procedure supplies: $5$ packs at a cost of $\\$10$ per pack.\n\nThe total mean cost for the cryotherapy strategy is:\n$$C_{CRYO} = (5 \\times 90) + (5 \\times 10)$$\n$$C_{CRYO} = 450 + 50 = 500$$\nThus, the mean cost per patient for the cryotherapy strategy is $\\$500$.\n\nNext, we identify the effectiveness for each strategy. The effectiveness is defined as the probability of complete wart clearance by week $12$. Let $E_{IMI}$ and $E_{CRYO}$ represent the effectiveness for the imiquimod and cryotherapy strategies, respectively.\n- Probability of clearance for imiquimod, $E_{IMI} = 0.42$.\n- Probability of clearance for cryotherapy, $E_{CRYO} = 0.58$.\n\nThe incremental cost per additional clearance ($ICER$) for cryotherapy relative to imiquimod is calculated as the ratio of the difference in costs ($\\Delta C$) to the difference in effectiveness ($\\Delta E$).\n$$ICER = \\frac{\\Delta C}{\\Delta E} = \\frac{C_{CRYO} - C_{IMI}}{E_{CRYO} - E_{IMI}}$$\n\nWe compute the incremental cost, $\\Delta C$:\n$$\\Delta C = C_{CRYO} - C_{IMI} = 500 - 320 = 180$$\nThe incremental cost is $\\$180$.\n\nWe compute the incremental effectiveness, $\\Delta E$:\n$$\\Delta E = E_{CRYO} - E_{IMI} = 0.58 - 0.42 = 0.16$$\nThe incremental effectiveness is $0.16$.\n\nFinally, we substitute these differences into the $ICER$ formula to find the incremental cost per additional clearance:\n$$ICER = \\frac{180}{0.16} = 1125$$\n\nThe result is an incremental cost of $\\$1125$ to achieve one additional case of complete clearance when choosing cryotherapy over imiquimod. The problem specifies that the answer should be rounded to four significant figures. The value $1125$ already consists of four significant figures ($1$, $1$, $2$, and $5$), so no rounding is necessary.",
            "answer": "$$\\boxed{1125}$$"
        }
    ]
}